Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMG281S)

Drug Name
Carboplatin Drug Info
Synonyms
Azanide; Carbopaltin; Carboplatine; Carboplatino; Carboplatinum; Cbdca; Ercar; Paraplatin; Carboplatine [French]; Carboplatino [Spanish]; Carboplatinum [Latin]; C 2538; JM 8; Carboplatin (USAN); IUPAC: Azane; JM-8; Paraplatin (TN); Paraplatin, Carboplatin; Paraplatin-AQ; Cis-Diammine(cyclobutanedicarboxylato)platinumII; Platinum(+2) Cation; Carboplatin (JAN/USP/INN); Carboplatin [USAN:INN:BAN:JAN]; Cyclobutane-1,1-dicarboxylate; Cyclobutane-1,1-dicarboxylic acid; Diammine-1,1-cyclobutane dicarboxylate platinum II; Cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato) platinum; Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; Cis-Diammine[1,1-cyclobutane-dicarboxylato] platinum; Diammine(1,1-cyclobutanedicarboxylato)platinum (II); Platinum, {diammine[1,1-cyclobut; Cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); Cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II); Cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); Platinum(II), (1, 1-cyclobutanedicar; Diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum; Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum; Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2); (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum; 1,1-Cyclobutanedicarboxylate diammine platinum (II); 1,1-Cyclobutanedicarboxylate diammine platinum(II)
Indication
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Approved [1]
Carcinoma 2A00-2F9Z Approved [1]
Cholangiocarcinoma 2C12.10 Approved [1]
Cutaneous melanoma 2C30 Approved [1]
Epithelial ovarian cancer 2B5D Approved [1]
Fallopian tube neoplasm Approved [1]
Gastroesophageal junction adenocarcinoma 2B71 Approved [1]
Lung adenocarcinoma Approved [1]
Lung cancer 2C25.0 Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [1]
Ovarian cancer 2C73 Approved [2]
Ovarian disorder Approved [1]
Ovarian neoplasm Approved [1]
Ovarian serous cystadenocarcinoma Approved [1]
Small-cell lung cancer 2C25.Y Approved [1]
Lung large cell carcinoma Investigative [1]
Neuroblastoma 2D11.2 Investigative [1]
Therapeutic Class
Anticancer Agents
Cross-matching ID
PubChem CID
426756
ChEBI ID
CHEBI:31355
CAS Number
CAS 41575-94-4
TTD Drug ID
DMG281S
VARIDT Drug ID
DR00469
INTEDE Drug ID
DR0272
ACDINA Drug ID
D00913

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Human Deoxyribonucleic acid (hDNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [6]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [7]
Daunorubicin DMQUSBT Acute monocytic leukemia Approved [8]
Ifosfamide DMCT3I8 Adult central nervous system germ cell tumor Approved [9]
Cyclophosphamide DM4O2Z7 Advanced cancer 2A00-2F9Z Approved [10]
Busulfan DMXYJ9C Chronic myelogenous leukaemia 2A20.0 Approved [11]
Procarbazine DMIK367 Hodgkin lymphoma 2B30 Approved [12]
Dactinomycin DM2YGNW Adult kidney Wilms tumor Approved [13]
Dacarbazine DMNPZL4 Adenocarcinoma 2D40 Approved [14]
Melphalan DMOLNHF Hematologic disease 3C0Z Approved [15]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By High affinity copper uptake protein 1 (SLC31A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [4]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [16]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [17]
Drug(s) Metabolized By Glutathione S-transferase pi (GSTP1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [18]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [19]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [5]
Busulfan DMXYJ9C Chronic myelogenous leukaemia 2A20.0 Approved [20]
Chlorambucil DMRKE63 Chronic lymphocytic leukaemia 2A82.0 Approved [21]
Drug(s) Metabolized By Glutathione S-transferase theta-1 (GSTT1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [18]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [19]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [5]
Drug(s) Metabolized By Metallothionein-1A (MT1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [22]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [5]
Drug(s) Metabolized By Metallothionein-2A (MT2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [22]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [5]
Drug(s) Metabolized By Myeloperoxidase (MPO)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [23]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [5]
Dapsone DM4LT8A Acne vulgaris ED80 Approved [24]
Ticlopidine DMO946V Acute coronary syndrome BA41 Approved [24]
Cysteamine DMSYFM8 Nephropathic cystinosis 5C60 Approved [25]
Glutethimide DMGE0CW Insomnia 7A00-7A0Z Approved [26]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Metabolized By Quinone reductase 1 (NQO1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [27]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [5]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [5]
Beta-Lapachone DMMI84K Solid tumour/cancer 2A00-2F9Z Phase 2 [28]
CB1954 DMVP4YK Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 2 [29]
Nitrobenzanthrone DMN6L70 N. A. N. A. Investigative [30]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Metabolized By Glutathione S-transferase mu-1 (GSTM1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [18]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [5]
Busulfan DMXYJ9C Chronic myelogenous leukaemia 2A20.0 Approved [20]
Azathioprine DMMZSXQ Lupus nephritis 4A40.0Y Approved [31]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [3]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
High affinity copper uptake protein 1 (SLC31A1) DTP8L4F COPT1_HUMAN Substrate [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Quinone reductase 1 (NQO1) DENP5RY NQO1_HUMAN Substrate [5]
Glutathione S-transferase pi (GSTP1) DEK6079 GSTP1_HUMAN Substrate [5]
Metallothionein-1A (MT1A) DE5ME8A MT1A_HUMAN Substrate [5]
Myeloperoxidase (MPO) DEA3U9Y PERM_HUMAN Substrate [5]
Metallothionein-2A (MT2A) DEFKGT7 MT2_HUMAN Substrate [5]
Glutathione S-transferase mu-1 (GSTM1) DEYZEJA GSTM1_HUMAN Substrate [5]
Glutathione S-transferase theta-1 (GSTT1) DE3PKUG GSTT1_HUMAN Substrate [5]

References

1 Carboplatin FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7624).
3 Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
4 Overcoming platinum drug resistance with copper-lowering agents. Anticancer Res. 2013 Oct;33(10):4157-61.
5 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
6 Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9.
7 Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.
8 31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12.
9 Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
10 O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
11 DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8.
12 Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86.
13 Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.
14 Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8.
15 Alkylation of DNA by melphalan in relation to immunoassay of melphalan-DNA adducts: characterization of mono-alkylated and cross-linked products fr... Chem Biol Interact. 1990;73(2-3):183-94.
16 Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol. 2005 Jan;53(1):13-23.
17 Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci. 2010 Jul 14;30(28):9500-9.
18 Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000 Sep;11(8):639-43.
19 Reactions of glutathione with the catechol, the ortho-quinone and the semi-quinone free radical of etoposide. Consequences for DNA inactivation. Biochem Pharmacol. 1992 Apr 15;43(8):1761-8.
20 Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos. 1996 Sep;24(9):1015-9.
21 The anti-cancer drug chlorambucil as a substrate for the human polymorphic enzyme glutathione transferase P1-1: kinetic properties and crystallographic characterisation of allelic variants. J Mol Biol. 2008 Jun 27;380(1):131-44.
22 Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer. 2000 Mar 15;85(6):777-81.
23 Cisplatin reduces Brucella melitensis-infected cell number by inducing apoptosis, oxidant and pro-inflammatory cytokine production. Res Vet Sci. 2010 Apr;88(2):218-26.
24 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
25 Thiols as peroxidase substrates. Free Radic Biol Med. 1993 Feb;14(2):167-75.
26 Proteomic profile of aminoglutethimide-induced apoptosis in HL-60 cells: role of myeloperoxidase and arylamine free radicals. Chem Biol Interact. 2015 Sep 5;239:129-38.
27 Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52.
28 Beta-lapachone, a modulator of NAD metabolism, prevents health declines in aged mice. PLoS One. 2012;7(10):e47122.
29 Gene Therapy of the Central Nervous System. Charter 22 - Prodrug-Activation Gene Therapy. 2006, Pages 291-301
30 Dose-dependent response to 3-nitrobenzanthrone exposure in human urothelial cancer cells. Chem Res Toxicol. 2017 Oct 16;30(10):1855-1864.
31 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA2040)